Clinical trial
Phase 3
Interventional
Ages 18 and up
Effect of Retatrutide Compared With Semaglutide in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin With or Without SGLT2 Inhibitor (TRANSCEND-T2D-2)
Run by Eli Lilly and Company · NCT06260722 · Data updated 2026-11-12
Fully enrolled, still running. This study is not taking new participants. Its registered completion date is 2026-08-27.
The purpose of this study is to investigate the efficacy and safety of retatrutide compared with semaglutide in participants with Type 2 Diabetes and inadequate glycemic control with metformin with or without sodium-glucose cotransporter-2 inhibitor (SGLT2i). The study will last about 26 months and may include up to 24 visits.
Quick facts
| Phase | Phase 3 |
|---|---|
| Study type | Interventional |
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 1250 (estimated) |
| Sponsor | Eli Lilly and Company Industry-sponsored |
| Drugs / interventions | Retatrutide, Semaglutide |
| Locations | 77 sites (Argentina, Canada, Mexico, Puerto Rico, United States) |
| Trial ID | NCT06260722 on ClinicalTrials.gov |
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Have Type 2 Diabetes (T2D) * Have HbA1c ≥ 7.0% (53 millimoles per mole (mmol/mol)) to ≤ 10.5% (91 mmol/mol) * Have been on a stable diabetes treatment consisting of metformin ≥ 1500 milligrams per day (mg/day) with or without SGLT2i during 90 days prior to screening * Are of stable weight for at least 90 days prior to screening * Have a Body Mass Index (BMI) ≥ 25.0 kilograms per meter squared (kg/m\^2) Exclusion Criteria: * Have Type 1 Diabetes (T1D) * Have a history of ketoacidosis or hyperosmolar state or coma within the last 6 months prior to screening * Have a history of severe hypoglycemia or hypoglycemia unawareness within the last 6 months prior to screening * Are currently receiving or planning to receive treatment for diabetic retinopathy and/or macular edema * Have an estimated glomerular filtration rate (eGFR) \<45 milliliters/minute/1.73 meter squared (mL/min/1.73 m\^2) or lower than the country-specific threshold for discontinuing metformin therapy per local label as determined by the central laboratory * Have a prior or planned surgical treatment for obesity * Have New York Heart Association Functional Classification IV congestive heart failure * Have had an acute myocardial infarction, stroke, or were hospitalized for congestive heart failure within 90 days prior to screening * Have a known clinically significant gastric emptying abnormality * Have a history of an active or untreated malignancy or are in remission from a clinically significant malignancy for less than 5 years * Have any lifetime history of a suicide attempt * Had chronic or acute pancreatitis * Have a family or personal history of medullary thyroid carcinoma or multiple endocrine neoplasia (MEN) syndrome Type 2 * Have taken prescribed or over-the-counter medication, or alternative remedies, intended to promote body weight reduction within 90 days prior to screening.
Where it's running
-
University of Alabama - Department of Nutrition Sciences
Birmingham, Alabama, United States -
Neighborhood Healthcare Institute of Health
Escondido, California, United States -
Long Beach Research Institute
Long Beach, California, United States -
Valley Clinical Trials, Inc.
Northridge, California, United States -
Rancho Cucamonga Clinical Research
Rancho Cucamonga, California, United States -
University of Colorado Anschutz Medical Campus
Aurora, Colorado, United States
Show 44 more locations
-
Arrow Clinical Trials
Daytona Beach, Florida, United States -
New Age Medical Research Corporation
Miami, Florida, United States -
South Broward Research
Miramar, Florida, United States -
Clinical Research of Central Florida
Winter Haven, Florida, United States -
Herman Clinical Research
Suwanee, Georgia, United States -
North Georgia Clinical Research
Woodstock, Georgia, United States -
Pacific Diabetes & Endocrine Center
Honolulu, Hawaii, United States -
Rocky Mountain Clinical Research
Idaho Falls, Idaho, United States -
Deaconess Clinic - Gateway Health Center
Newburgh, Indiana, United States -
IMA Clinical Research Monroe - Armand
Monroe, Louisiana, United States -
MedStar Health Research Institute (MedStar Physician Based Research Network)
Hyattsville, Maryland, United States -
Brigham and Women's Hospital Diabetes Program
Boston, Massachusetts, United States -
NECCR PrimaCare Research
Fall River, Massachusetts, United States -
Arcturus Healthcare , PLC, Troy Internal Medicine Research Division
Troy, Michigan, United States -
Palm Research Center Tenaya
Las Vegas, Nevada, United States -
Palm Research Center Sunset
Las Vegas, Nevada, United States -
NYC Research INC
Long Island City, New York, United States -
Medication Management
Greensboro, North Carolina, United States -
Remington Davis Clinical Research
Columbus, Ohio, United States -
Alliance for Multispecialty Research, LLC
Norman, Oklahoma, United States -
Central States Research
Tulsa, Oklahoma, United States -
The Corvallis Clinic, P.C.
Corvallis, Oregon, United States -
Thomas Jefferson University Hospital
Philadelphia, Pennsylvania, United States -
Velocity Clinical Research, Dallas
Dallas, Texas, United States -
Valley Institute of Research - Fort Worth
Fort Worth, Texas, United States -
Juno Research
Houston, Texas, United States -
Southern Endocrinology Associates
Mesquite, Texas, United States -
Consano Clinical Research, LLC
Shavano Park, Texas, United States -
Texas Valley Clinical Research
Weslaco, Texas, United States -
Medrasa Clinical Research
Wylie, Texas, United States -
Central Washington Health Services Association d/b/a Confluence Health
Wenatchee, Washington, United States -
IMA Clinical Research West Virginia
Morgantown, West Virginia, United States -
CARE - Centro de Alergia y Enfermedades Respiratorias
Ciudad Autónoma de Buenos Aires, Buenos Aires, Argentina -
Stat Research S.A.
Buenos Aires, Buenos Aires F.D., Argentina -
Ciprec
Buenos Aires, Buenos Aires F.D., Argentina -
Centro Médico Viamonte
Buenos Aires, Buenos Aires F.D., Argentina -
Mautalen Salud e Investigación
Buenos Aires, Buenos Aires F.D., Argentina -
Centro Medico Dra. Laura Maffei- Investigacion Clinica Aplicada
Buenos Aires, Buenos Aires F.D., Argentina -
Cemediab
C.a.b.a., Buenos Aires F.D., Argentina -
Instituto Centenario
Caba, Buenos Aires F.D., Argentina -
Centro Medico Privado San Vicente Diabetes
Córdoba, Córdoba Province, Argentina -
CIPADI - Centro Integral de Prevencion y Atencion en Diabetes
Godoy Cruz, Mendoza Province, Argentina -
Centro de Investigaciones Clínicas Baigorria
Granadero Baigorria, Santa Fe Province, Argentina -
Instituto de Investigaciones Clinicas Rosario
Rosario, Santa Fe Province, Argentina
+27 more sites. See ClinicalTrials.gov for the full list.
Study contacts
- Principal investigator: Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST) — Eli Lilly and Company
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Browse more
Last reviewed 2026-11-16 by the Find a Trial editorial team.
Information on this page is for educational purposes and is not medical advice.
Always consult qualified healthcare professionals about clinical trial participation.